AffyMax Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 72

Employees

  • Stock Symbol
  • AFFY

Stock Symbol

AffyMax General Information

Description

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S. It operates in one reportable segment, Marine Contracting.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 600 Fifth Avenue
  • 2nd Floor
  • New York, NY 10020
  • United States
+1 (650)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
OTCM
Vertical(s)
Life Sciences
Corporate Office
  • 600 Fifth Avenue
  • 2nd Floor
  • New York, NY 10020
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AffyMax Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
5.19K

AffyMax Financials Summary

As of 30-Jun-2014, AffyMax has a trailing 12-month revenue of $42K.

In Thousands,
USD 		TTM 30-Jun-2014 FY 2013 31-Dec-2013 FY 2012 31-Dec-2012 FY 2011 31-Dec-2011
EV (1,051) 22,390 636,650 120,931
Revenue 42 1,369 94,370 47,720
EBITDA 2,694 (14,316) (90,086) (59,209)
Net Income 2,694 (14,424) (93,412) (61,367)
Total Assets 5,384 7,443 118,217 118,995
Total Debt 0 0 8,844 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AffyMax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AffyMax‘s full profile, request access.

Request a free trial

AffyMax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for
Pharmaceuticals
New York, NY
72 As of 2015

Carlsbad, CA

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AffyMax Competitors (24)

One of AffyMax’s 24 competitors is Renova Therapeutics, a Venture Capital-Backed company based in Carlsbad, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
AB Science Formerly Accelerator/Incubator backed Paris, France
Nippon Shinyaku Corporation Kyoto, Japan
Mesoblast Corporation Melbourne, Australia
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 5 of 24 competitors. Get the full list »

AffyMax Patents

  • 404

    Total Documents Applications and Grants

  • Total Patents Families

  • 55

    Granted

  • 13

    Pending

  • Expiring in next 12 mo

AffyMax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2009191056-A Therapy of disorder mediated by anti-erythropoietin antibody using epo receptor agonist based on synthetic peptide Pending 15-Feb-2008
US-20090209457-A1 Treatment of anti-erythropoietin antibody-mediated disorders with synthetic peptide-based epo receptor agonists Inactive 15-Feb-2008
US-20090124709-A1 Analytical methods for validating excipient purity Inactive 10-Sep-2007
WO-2009025958-A1 Erythropoietin rceptor peptide formulations and uses Inactive 22-Aug-2007
EP-2195002-A1 Erythropoietin receptor peptide formulations and uses Inactive 22-Aug-2007 C07K14/4705
To view AffyMax’s complete patent history, request access »

AffyMax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AffyMax Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AffyMax‘s full profile, request access.

Request a free trial

AffyMax FAQs

  • When was AffyMax founded?

    AffyMax was founded in 2001.

  • Where is AffyMax headquartered?

    AffyMax is headquartered in New York, NY.

  • What is the size of AffyMax?

    AffyMax has 72 total employees.

  • What industry is AffyMax in?

    AffyMax’s primary industry is Pharmaceuticals.

  • Is AffyMax a private or public company?

    AffyMax is a Public company.

  • What is AffyMax’s stock symbol?

    The ticker symbol for AffyMax is AFFY.

  • What is AffyMax’s current revenue?

    The trailing twelve month revenue for AffyMax is $42K.

  • Who are AffyMax’s competitors?

    Renova Therapeutics, AB Science, Nippon Shinyaku, Mesoblast, and ACADIA Pharmaceuticals are some of the 24 competitors of AffyMax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process